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Editor: L. LeiboviciIt was not until 24 March 2020 that the newly developed BioFire
coronavirus disease 2019 (COVID-19) test (BioFire Defense, Salt Lake
City, UT, USA) for PCR-based detection of RNA from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical sam-
ples received a US Food and Drug Administration emergency-use
authorization (https://www.fda.gov/media/136356/download). It is
thus not surprising that no published studies to date have evaluated
the BioFire COVID-19 test in clinical microbiology practice.
We compared the performance of BioFire COVID-19 test with
that of Quanty COVID-19 assay (Clonit, Milan, Italy), which also
provides quantitative results, for detection of SARS-CoV-2 RNA in
nasal/oropharyngeal (N/OP) patient samples. Both molecular tests
detect SARS-CoV-2 specifically, with the first targeting two viral
open reading frame (ORF) sequences (ORF1ab and ORF8)din three
independent PCR assaysdand the second targeting three viral* Corresponding author: Maurizio Sanguinetti, Dipartimento di Scienze di Lab-
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essential for defining the cause of potential false-negative results
[1], which may undermine the clinical utility of various molecular
diagnostic tests available currently [2,5].
We analysed the results of 120 N/OP samples tested with both
the BioFire COVID-19 test and the Quanty COVID-19 assay. Samples
that had been kept frozen at 70C until testing to ensure RNA
integrity were randomly selected from among those that were
SARS-CoV-2 positive (n ¼ 86) and negative (n ¼ 34), as tested with
the Allplex 2019-nCoV assay (Arrow Diagnostics, Genova, Italy) [3],
and then confirmed (as positive or negative respectively) by a real-
time PCR assay (here used as the reference method) based on the
Corman et al. method [4]. The agreement between the BioFire
COVID-19 test and Quanty COVID-19 assay was 95.0% (114/120) for
overall results and 100% (34/34) for negative results. Eighty (93.0%)
of 86 positive samples yielded results with the BioFire COVID-19
test that matched those with the Quanty COVID-19 assay. For six
remaining positive samples, BioFire COVID-19 test results did not
match those with the Quanty COVID-19 assay. As shown in
Supplementary Table S1, two of six samplesdfalsely negative by
BioFire COVID-19 testdhad no detections in all three assays (hence
interpreted as ‘not detected’), whereas four samples initially yiel-
ded detection in only one assay (hence interpreted as ‘equivocal’)
but resulted as ‘not detected’ at retesting. Interestingly, virus loads
(expressed as RNA copies/mL) of the six samples were 2.20 101 to
1.60  102. However, these loads were below the limit of detection
of 3.30  102 RNA copies/mL estimated for the BioFire COVID-19
test (https://www.biofiredefense.com/covid-19test/). In 80 sam-
ples with results agreeing between the assays, the median (inter-
quartile range) virus load was 7.89  103 (2.48  103e2.75  105)
RNA copies/mL, whichwas consistent with an average (range) value
of 1.24  108 (3.82  102e7.83  109) RNA copies/mL. Compared to
the reference method, the BioFire COVID-19 test sensitivity, speci-
ficity, positive predictive value and negative predictive value (with
their 95% confidence intervals) were 93.0 (85.4e97.4), 100.0ublished by Elsevier Ltd. All rights reserved.
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respectively.
These findings suggest that the lower analytical sensitivity of
the BioFire COVID-19 test might have caused false-negative results
in our study. Consequently, compared tomolecular tests such as the
Quanty COVID-19 assay, the analytical sensitivity shown by BioFire
COVID-19 test would result in a slight reduction in its clinical
sensitivity in COVID-19 diagnosis. Additionally, ‘equivocal’ results
that at repeated testing with the BioFire COVID-19 test are claimed
as ‘not detected’ may actually be truly positive, but this requires
further investigation. Relying on fully automated FilmArray plat-
forms, BioFire COVID-19 test provides results in approximately
45 minutes from N/OP sample collection. Thus, the possibility of
shortening the time to results merits consideration when deciding
which SARS-CoV-2 molecular test to implement in the clinical
microbiology laboratory.Transparency declaration
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Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.cmi.2020.07.026.
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